Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03518034 · ClinicalTrials.gov registry record · Phase 4
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
A Phase 4 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 4
- Development phase
- 5,246
- Enrollment target
NCT03518034 is a Phase 4 study that has completed, run by AbbVie. The registered enrollment target is 5,246 participants.
The verdict
NCT03518034, a Phase 4 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5,246 participants
- Enrollment target
Study Summary
This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
Interventions
- DRUG Placebo
- DRUG AndroGel®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,246 participants |
| Start Date | 2018-05-03 |
| Est. Completion | 2023-01-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03518034
The ClinicalTrials.gov registry entry for NCT03518034 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5,246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03518034 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03518034 about?
NCT03518034 is a clinical study titled "A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men". This is a double-blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with pre-existing cardiovascular disease (CVD) or increased risk for CVD.
What is the current status of trial NCT03518034?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5,246 participants. The study started on 2018-05-03. Estimated completion is 2023-01-19.
What interventions are being tested in trial NCT03518034?
The interventions under investigation include: Placebo (DRUG), AndroGel® (DRUG).
Who is sponsoring clinical trial NCT03518034?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.